

August 3, 2016



Syros Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference. Details are as follows:

Wedbush PacGrow Healthcare Conference

Date: Tuesday, August 16

Time: 10:55 a.m.

Location: Le Parker Meridien Hotel, 119 West 56th Street, New York, NY

A live webcast of the presentation will be available on the News & Investors section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company's gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RAR α agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160803005197/en/>

Media Contact:

Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com

or

Investor Contact:

Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com

Source: Syros Pharmaceuticals